Market Insights report
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.
What's included?
Anti-Fibrinolytic Drugs are used to treat serious bleeding. A significant share of the Anti-Fibrinolytics market is dominated by only a small number of drugs, yet the revenue per drug is not as high as in many other markets. Throughout the time period considered, anti-fibrinolytics revenue shows steady growth. The negative impact of the COVID-19 pandemic, i.e., fewer new patients and canceled or postponed surgeries, is not reflected in the overall market figures because of the rollout of Roche's Hemlibra in 2020.
Overview
Market numbers
We provide information on industries, companies, consumers, trends, countries, and politics, covering the latest and most important issues in a condensed format.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)